Krystal Biotech

Yahoo Finance • 14 days ago

Krystal Biotech gets expanded FDA approval for Vyjuvek

[Male Medical Researcher] FatCamera/iStock via Getty Images Krystal Biotech (NASDAQ:KRYS [https://seekingalpha.com/symbol/KRYS]) announced that the FDA has approved an updated label for its gene therapy, Vyjuvek (beremagene geperpavec).... Full story

Yahoo Finance • 15 days ago

Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

Revised label allows treatment of DEB patients from birth VYJUVEK can now be applied by patients and caregivers PITTSBURGH, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that th... Full story

Yahoo Finance • last month

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

PITTSBURGH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB707, the Company’s redosable immunotherapy... Full story

Yahoo Finance • 2 months ago

Krystal Biotech price target lowered to $182 from $192 at BofA

BofA analyst Alec Stranahan lowered the firm’s price target on Krystal Biotech (KRYS) to $182 from $192 and keeps a Buy rating on the shares. While there were some positives from the Q2 report, the firm expects investors will be concerned... Full story

Yahoo Finance • 2 months ago

KRYSTAL BIOTECH INC (NASDAQ:KRYS) Q2 2025 Earnings Beat Estimates as VYJUVEK Drives Strong Revenue Growth

KRYSTAL BIOTECH INC (NASDAQ:KRYS [https://www.chartmill.com/stock/quote/KRYS]) reported second-quarter 2025 financial results, with revenue and earnings per share (EPS) surpassing analyst expectations. The company’s performance, particular... Full story

Yahoo Finance • 2 months ago

Krystal Biotech, Inc. Q2 Profit Advances, But Misses Estimates

(RTTNews) - Krystal Biotech, Inc. (KRYS) released earnings for its second quarter that Increases, from the same period last year but missed the Street estimates. The company's bottom line totaled $38.33 million, or $1.29 per share. This... Full story

Yahoo Finance • 2 months ago

Krystal Biotech GAAP EPS of $1.29 beats by $0.16, revenue of $96.04M beats by $4.08M

* Krystal Biotech press release [https://seekingalpha.com/pr/20187226-krystal-biotech-announces-second-quarter-2025-financial-and-operating-results] (NASDAQ:KRYS [https://seekingalpha.com/symbol/KRYS]): Q2 GAAP EPS of $1.29 beats by $0.1... Full story

Yahoo Finance • 2 months ago

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH, July 24, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune... Full story

Yahoo Finance • 2 months ago

Krystal biotech (KRYS) director Suma Krishnan sells $5.39m in stock

Suma Krishnan, a Director and President, R&D at Krystal Biotech , Inc. (NASDAQ:KRYS), sold a total of $5.39 million in company stock between July 14 and July 16, 2025. The sales, executed under a pre-arranged 10b5-1 trading plan, involved... Full story

Yahoo Finance • 2 months ago

Krishnan Krish S, Krystal Biotech CEO, sells $5.39 million in stock

Krystal Biotech (NASDAQ:KRYS), a $4.3 billion biotechnology company with impressive gross profit margins of 93.2%, reported insider selling activity. President and CEO Krishnan Krish S, along with his spouse, sold shares of common stock b... Full story

Yahoo Finance • 3 months ago

Krystal Biotech begins phase 1/2 trial of eye drop gene therapy for NK

PITTSBURGH - Krystal Biotech, Inc. (NASDAQ:KRYS), a $4.1 billion biotech company with impressive 93% gross profit margins according to InvestingPro data, has dosed the first patient in its Phase 1/2 clinical trial evaluating KB801, an inve... Full story

Yahoo Finance • 3 months ago

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design PITTSBURGH, July 09, 2025 (GLOBE NEWS... Full story

Yahoo Finance • 3 months ago

Is Venezuela about to lose Citgo, its most prized foreign asset?

By Marianna Parraga HOUSTON (Reuters) -A U.S. court has received last-minute improved bids in a auction of shares in the parent of Venezuela-owned Citgo Petroleum from at least three consortia, potentially raising the price tag for the se... Full story

Yahoo Finance • 3 months ago

Clear Street initiates Krystal Biotech stock with Buy rating, $190 target

Investing.com - Clear Street initiated coverage on Krystal Biotech (NASDAQ:KRYS) with a Buy rating and a $190 price target on Monday. According to InvestingPro data, the company currently trades at an attractive PEG ratio of 0.3, suggest... Full story

Yahoo Finance • 3 months ago

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

Key Points The healthcare sector offers an abundance of high-growth investment opportunities. Companies leveraging artificial intelligence and genomic medicine are delivering innovative therapies with significant potential. Small-cap and... Full story

Yahoo Finance • 3 months ago

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

Intra-patient, double-blind, multicenter, placebo-controlled study with crossover design Repeat administration under compassionate use was previously shown to be well tolerated and associated with full corneal healing by 3 months as well... Full story

Yahoo Finance • 5 months ago

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundament... Full story

Yahoo Finance • 6 months ago

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamenta... Full story

Yahoo Finance • 7 months ago

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medi... Full story

Yahoo Finance • 7 months ago

Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023 Full year revenues increased 473% to $290.5 million versus 2023 CFF TDN granted full sanctioning of KB407 Phase 1 protocol Strong balance sheet, endin... Full story